Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
Nektar Therapeutics (NKTR) shares soared 12.1% in the last trading session to close at $9.54. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 13.2% loss over the past four weeks.
The stock rallied as investor optimism grew over the company's review of top-line data from the phase IIb REZOLVE-AD study evaluating its pipeline candidate, rezpegaldesleukin, for treating moderate-to-severe atopic dermatitis.
This biopharmaceutical company is expected to post quarterly loss of $2.53 per share in its upcoming report, which represents a year-over-year change of +32.5%. Revenues are expected to be $10.78 million, down 54.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Nektar, the consensus EPS estimate for the quarter has been revised 10.5% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on NKTR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Nektar belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Indivior PLC (INDV), closed the last trading session 0.4% lower at $13.95. Over the past month, INDV has returned 24.4%.
For Indivior, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.25. This represents a change of -43.2% from what the company reported a year ago. Indivior currently has a Zacks Rank of #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Nektar Therapeutics (NKTR) : Free Stock Analysis Report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
Graco Inc. (GGG) : Free Stock Analysis Report
Stem, Inc. (STEM) : Free Stock Analysis Report
Compugen Ltd. (CGEN) : Free Stock Analysis Report
Modine Manufacturing Company (MOD) : Free Stock Analysis Report
Liberty Media Corporation - Liberty Formula One Series A (FWONA) : Free Stock Analysis Report
Sutro Biopharma, Inc. (STRO) : Free Stock Analysis Report
Progyny, Inc. (PGNY) : Free Stock Analysis Report
Indivior PLC (INDV) : Free Stock Analysis Report
Cartesian Therapeutics, Inc. (RNAC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Walgreens Boots Alliance (WBA) Q3 Earnings and Revenues Beat Estimates
Walgreens Boots Alliance (WBA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +11.76%. A quarter ago, it was expected that this largest U.S. drugstore chain would post earnings of $0.53 per share when it actually produced earnings of $0.63, delivering a surprise of +18.87%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Walgreens, which belongs to the Zacks Retail - Pharmacies and Drug Stores industry, posted revenues of $38.99 billion for the quarter ended May 2025, surpassing the Zacks Consensus Estimate by 6.49%. This compares to year-ago revenues of $36.35 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Walgreens shares have added about 21.2% since the beginning of the year versus the S&P 500's gain of 3.6%. While Walgreens has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Walgreens was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.25 on $36.98 billion in revenues for the coming quarter and $1.69 on $151.46 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Retail - Pharmacies and Drug Stores is currently in the top 2% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the broader Zacks Retail-Wholesale sector, Genuine Parts (GPC), has yet to report results for the quarter ended June 2025. This auto and industrial parts distributor is expected to post quarterly earnings of $2.08 per share in its upcoming report, which represents a year-over-year change of -14.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Genuine Parts' revenues are expected to be $6.11 billion, up 2.6% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report Genuine Parts Company (GPC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Lindsay (LNN) Surpasses Q3 Earnings and Revenue Estimates
Lindsay (LNN) came out with quarterly earnings of $1.78 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.41 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +30.88%. A quarter ago, it was expected that this irrigation equipment maker would post earnings of $1.89 per share when it actually produced earnings of $2.44, delivering a surprise of +29.1%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Lindsay, which belongs to the Zacks Manufacturing - Farm Equipment industry, posted revenues of $169.46 million for the quarter ended May 2025, surpassing the Zacks Consensus Estimate by 4.60%. This compares to year-ago revenues of $139.2 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Lindsay shares have added about 16% since the beginning of the year versus the S&P 500's gain of 3.6%. While Lindsay has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Lindsay was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.20 on $161.38 million in revenues for the coming quarter and $6.57 on $676.71 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Manufacturing - Farm Equipment is currently in the bottom 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Avery Dennison (AVY), another stock in the broader Zacks Industrial Products sector, has yet to report results for the quarter ended June 2025. This maker of office products is expected to post quarterly earnings of $2.39 per share in its upcoming report, which represents a year-over-year change of -1.2%. The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level. Avery Dennison's revenues are expected to be $2.23 billion, down 0.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lindsay Corporation (LNN) : Free Stock Analysis Report Avery Dennison Corporation (AVY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Walgreens: Fiscal Q3 Earnings Snapshot
DEERFIELD, Ill. (AP) — DEERFIELD, Ill. (AP) — Walgreens Boots Alliance Inc. (WBA) on Thursday reported a loss of $175 million in its fiscal third quarter. The Deerfield, Illinois-based company said it had a loss of 20 cents per share. Earnings, adjusted for amortization costs and non-recurring costs, came to 38 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 34 cents per share. The largest U.S. drugstore chain posted revenue of $38.99 billion in the period, which also beat Street forecasts. Five analysts surveyed by Zacks expected $36.61 billion. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on WBA at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
